Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 277 results for "mirati"

Mirati Therapeutics Receives Orphan Designation from U.S. Food...

By a News Reporter-Staff News Editor at Clinical Trials Week Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell ... Pharmacy Choice, 1 day ago
[x]  

2 images for "mirati"

Drug Discovery and Development, 2 weeks ago
worldnow.com, 2 weeks ago

Mirati Therapeutics misses by $0.13

Mirati Therapeutics (NASDAQ: MRTX ): Q2 EPS of -$0.82 misses by $0.13 . Press Release Post
 Seeking Alpha2 weeks ago Mirati Therapeutics (MRTX) Releases Quarterly Earnings, Misses Estimates By $0.13 EPS  American Banking News2 weeks ago

More on Mirati Q2 results

09:18 ET | About: Mirati Therapeutics, Inc. (MRTX) Mirati Therapeutics (NASDAQ:MRTX) Q2 results: Revenues: $0; Operating Loss: ($10.1M) (-46.4%); Net Loss: ($11.0M) (-37.5%); Loss Per Share: ($0.82) (-2.5%); Quick Assets: $47.4M (-23.7%). No ...
 Seeking Alpha2 weeks ago

Mirati Therapeutics Relocating in San Diego

Mirati Therapeutics Inc. entered into a triple net lease with ARE-SD Region No. 20 LLC for 18,000 square feet of office and laboratory space at 9393 Towne Centre Drive in San Diego, California. The office space will serve as new corporate ...
 CoStar Group1 month ago

Lease Up: Major Corporate Space Moves for the Week of June 30-July 4

Tenants Include: Foundation Medicine, Health Partners, Intralinks, JKG Group, Mast Therapeutics, Mirati Therapeutics, Nationwide Mutual, Relypsa, San Jose Mercury News and Vineyard Vines Nationwide Mutual Planning New 500,000-SF Campus In a ...
 CoStar Group1 month ago

Mirati Therapeutics Q2 net loss increases

(MarketLine via COMTEX News Network) -- Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported that net loss for the second quarter ended June 30, 2014 was $11.04 million, or $0.82 loss per share, compared to a net loss ...
 PredictWallStreet1 day ago

8-K - Mirati Therapeutics, Inc. (0001576263) (Filer)

Filing Date 2014-08-08 Accepted 2014-08-08 16:01:50 Documents 3 Period of Report 2014-08-08 Filing Date Changed 2014-08-08 Items Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial ...
 SEC Filings2 weeks ago

Johnson Rice Upgrades Mirati Therapeutics to Focus List (MRTX)

Mirati Therapeutics (NASDAQ:MRTX) opened at 18.30 on Friday. Mirati Therapeutics has a 1-year low of $7.00 and a 1-year high of $25.97. The stock's 50-day moving average is $20.28 and its 200-day moving average is $19.79. The company's market cap is ...
 American Banking News1 month ago

Mirati Therapeutics Now Covered by Brean Capital (MRTX)

Investment analysts at Brean Capital began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) In other Mirati Therapeutics news, major shareholder Orbimed Advisors Llc sold 107,332 shares of Mirati Therapeutics stock on the open market in a ...
 American Banking News1 month ago

Mirati Therapeutics Sees Large Decline in Short Interest (MRTX)

Shares of Mirati Therapeutics (NASDAQ:MRTX) were the recipient of a significant decline in short interest in the month of June. As of June 13th, there was short interest totalling 393,398 shares, a decline of 28.6% from the May 30th total of 550,920 ...
 American Banking News1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less